Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Mark E. Dmytruk Sells 39,569 Shares

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Free Report) insider Mark E. Dmytruk sold 39,569 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $1.21, for a total value of $47,878.49. Following the completion of the transaction, the insider now directly owns 761,737 shares of the company’s stock, valued at approximately $921,701.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ginkgo Bioworks Stock Performance

Shares of DNA opened at $1.29 on Wednesday. The stock has a market capitalization of $2.73 billion, a PE ratio of -2.80 and a beta of 1.29. The company’s fifty day moving average is $1.44 and its 200 day moving average is $1.65. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $2.55.

Ginkgo Bioworks (NYSE:DNAGet Free Report) last posted its earnings results on Wednesday, November 8th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). Ginkgo Bioworks had a negative net margin of 272.30% and a negative return on equity of 36.36%. The firm had revenue of $55.43 million for the quarter, compared to the consensus estimate of $46.47 million. As a group, research analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -0.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNA. Yousif Capital Management LLC bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth about $25,000. Spire Wealth Management bought a new stake in Ginkgo Bioworks in the fourth quarter worth about $25,000. Creative Planning purchased a new position in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $25,000. Silverlake Wealth Management LLC bought a new position in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $25,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Ginkgo Bioworks in the first quarter worth approximately $26,000. Hedge funds and other institutional investors own 56.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DNA. BTIG Research lowered shares of Ginkgo Bioworks from a “buy” rating to a “neutral” rating in a research report on Thursday, November 9th. Raymond James lowered Ginkgo Bioworks from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $3.50 to $2.50 in a research report on Tuesday, November 14th. Finally, The Goldman Sachs Group decreased their target price on Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating on the stock in a research report on Monday, January 22nd.

View Our Latest Analysis on Ginkgo Bioworks

About Ginkgo Bioworks

(Get Free Report)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Recommended Stories

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.